Hidden danger, obvious opportunity: Error and risk in the management of cancer

British Journal of Radiology

Volumn 80, Issue 960, 2007, Pages 955-966

  Munro, A J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACCREDITATION; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; CANCER THERAPY; CLINICAL PRACTICE; CULTURAL ANTHROPOLOGY; DOSIMETRY; FOLLOW UP; HAZARD ASSESSMENT; HEALTH PROGRAM; HUMAN; MEDICAL ERROR; MORTALITY; NEOPLASM; NOTE; PATIENT SAFETY; QUALITY CONTROL; RADIATION DOSE; RISK ASSESSMENT; RISK REDUCTION; SAFETY; TELETHERAPY; NOMENCLATURE; RADIATION INJURY; RADIOMETRY; RADIOTHERAPY; REVIEW;

HUMANS; MEDICAL ERRORS; NEOPLASMS; RADIATION INJURIES; RADIOMETRY; RADIOTHERAPY; RISK ASSESSMENT; TERMINOLOGY AS TOPIC;

EID: 38349010483     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/12777683     Document Type: Note

References (85)

1. Donaldson LJ. Radiotherapy: Hidden Dangers. In 2006 Annual Report of the Chief Medical Officer. On the State of the Public Health. London, UK: The Department of Health; 2006:34-39.
2. Thwaites D, Scalliet P, Leer JW, Overgaard J. Quality assurance in radiotherapy. European Society for Therapeutic Radiology and Oncology Advisory Report to the Commission of the European Union for the 'Europe Against Cancer Programme'. Radiother Oncol 1995;35:61-73.
3. Kohn LT, Corrigan JM, Donaldson MS. To Err Is Human: Building a Safer Health System. Washington DC: National Academies Press; 2000.
4. Department of Health. An organisation with a memory. Report of an expert group on learning from adverse events in the NHS chaired by the Chief Medical Officer. London, UK: The Department of Health; 2000.
5. Weingart SN. Beyond Babel: prospects for a universal patient safety taxonomy. Int J Qual Health Care 2005;17:93-4.
6. Chang A, Schyve PM, Croteau RJ, O'Leary DS, Loeb JM. The JCAHO patient safety event taxonomy: a standardized terminology and classification schema for near misses and adverse events. Int J Qual Health Care 2005;17:95-105.
7. World Alliance for Patient Safety Taxonomy. International Classification for Patient Safety (ICPS). Geneva: World Health Organisation; 2007.
8. Ekaette EU, Lee RC, Cooke DL, Kelly K-L, Dunscombe PB. Risk analysis in radiation treatment: Application of a new taxonomic structure. Radiother Oncol 2006;80:282-7.
9. Deaths from smoking. The hazards of smoking and the benefits of stopping. Available from: http://www. deathsfromsmoking.net/hazards.html [Accessed 1 October 2007].
10. Sari AB-A, Sheldon TA, Cracknell A, Turnbull A. Sensitivity of routine system for reporting patient safety incidents in an NHS hospital: retrospective patient case note review. Br Med J 2007;334:79.
11. Bandolier. NSAIDS and adverse events. Available from: www.jr2.ox.ac.uk/bandolier/booth/painpag/nsae/nsae.html [Accessed 1 October 2007].
12. Advisory Committee on Breast Cancer Screening, Austoker J, Beral V, Berrington A, Blanks RG. Screening for breast cancer in England: past and future. J Med Screen 2006;13:59-61.
13. International Atomic Energy Agency. Accidental overexposure of radiotherapy patients in San Jose, Costa Rica. Vienna: IAEA; 1998.
14. International Atomic Energy Agency. Investigation of an accidental exposure of radiotherapy patients in Panama. Vienna: IAEA; 2001.
15. International Atomic Energy Agency. Accidental overexposure of radiotherapy patients in Bialystok. Vienna: IAEA; 2004.
16. International Commission on Radiological Protection. Prevention of Accidental Exposures to Patients Undergoing Radiation Therapy. Report Number 86. Oxford, UK: Pergamon; 2000.
17. International Atomic Energy Agency. Lessons learned from accidental exposures in radiotherapy. Vienna: IAEA; 2000.
18. AAPM. A protocol for the determination of absorbed dose from high-energy photon and electron beams. Report of the American Association of Physicists in Medicine Radiation Therapy Committee Task Group No. 21. Med Phys 1993;10:741-71.
19. Kerr DJ. Two errors. Lancet 2004;364:907.
20. Thomas RJ, Williams M, Garcia-Vargas J. Lessons learned from raltitrexed-quality assurance, patient education and intensive supportive drugs to optimise tolerability. Clin Oncol (R Coll Radiol) 2003;15:227-32.
21. DuBeshter B, Walsh CJ, Altobelli K, Loughner J, Angel C Experience with computerized chemotherapy order entry. J Oncol Pract 2006;2:49-52.
22. Nebeker JR, Hoffman JM, Weir CR, Bennett CL, Hurdle JF. High rates of adverse drug events in a highly computerized hospital. Arch Intern Med 2005;165:1111-6.
23. Patton GA, Gaffney DK, Moeller JH. Facilitation of radiotherapeutic error by computerized record and verify systems. Int J Radiat Oncol Biol Phys 2003;56:50-7.
24. Gandhi TK, Weingart SN, Seger AC, Borus J, Burdick E, Poon EG, et al. Outpatient prescribing errors and the impact of computerized prescribing. J Gen Intern Med 2005;20:837-41.
25. Koppel R, Metlay JP, Cohen A, Abaluck B, Localio AR, Kimmel SE, et al. Role of computerized physician order entry systems in facilitating medication errors. JAMA 2005;293:1197-203.
26. McKenzie A, Briggs G, Buchanan R, Harvey L, Iles A, Kirby M. Balancing costs and benefits of checking in radiotherapy. Report No. 92. York: IPEM; 2006.
27. Evans P, Morgan-Fletcher S. Dosimetric measurements (photons). York: IPEM; 2006.
28. Harrison R, Morgan A. In-vivo dosimetry: hidden dangers? Br J Radiol 2007;80:691-2.
29. Edwards CR, Hamer E, Mountford PJ, Moloney AJ. An update survey of UK in-vivo radiotherapy dosimetry practice. Br J Radiol 2007;80:1010-3.
30. National Radiotherapy Advisory Group. Radiotherapy, developing a world class service for England. London, UK: Department of Health; 2007.
31. Radiotherapy Activity Planning Group. Cancer in Scotland; Radiotherapy Activity Planning in Scotland 2011-2015. Edinburgh: Scottish Executive Health Department; 2005.
32. Delaney G, Barton M, Jacob S. Estimation of an optimal radiotherapy utilization rate for breast carcinoma: a review of the evidence. Cancer 2003;98:1977-86.
33. Delaney G, Barton M, Jacob S. Estimation of an optimal radiotherapy utilization rate for gastrointestinal carcinoma: a review of the evidence. Cancer 2004;101:657-70.
34. Delaney G, Barton M, Jacob S. Estimation of an optimal radiotherapy utilization rate for melanoma: a review of the evidence. Cancer 2004;100:1293-301.
35. Delaney G, Barton M, Jacob S, Jalaludin B. A model for decision making for the use of radiotherapy in lung cancer. Lancet Oncol 2003;4:120-8.
36. Delaney G, Jacob S, Barton M. Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma; part II-carcinoma of the endometrium. Cancer 2004;101:682-92.
37. Delaney G, Jacob S, Barton M. Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma: part I-malignancies of the cervix, ovary, vagina and vulva. Cancer 2004;101:671-81.
38. Delaney G, Jacob S, Barton M. Estimation of an optimal external beam radiotherapy utilization rate for head and neck carcinoma. Cancer 2005;103:2216-27.
39. Delaney G, Jacob S, Barton M. Estimating the optimal external-beam radiotherapy utilization rate for genitourinary malignancies. Cancer 2005;103:462-73.
40. Delaney G, Jacob S, Barton M. Estimating the optimal radiotherapy utilization for carcinoma of the central nervous system, thyroid carcinoma, and carcinoma of unknown primary origin from evidence-based clinical guidelines. Cancer 2006;106:453-65.
41. Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 2005;104:1129-37.
42. Featherstone C, Delaney G, Jacob S, Barton M. Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: part I-lymphoma. Cancer 2005;103:383-92.
43. Featherstone C, Delaney G, Jacob S, Barton M. Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: part II-leukemia and myeloma. Cancer 2005;103:393-401.
44. Foroudi F, Tyldesley S, Barbera L, Huang J, Mackillop WJ. An evidence-based estimate of the appropriate radiotherapy utilization rate for colorectal cancer. Int J Radiat Oncol Biol Phys 2003;56:1295-307.
45. Foroudi F, Tyldesley S, Barbera L, Huang J, Mackillop WJ. Evidence-based estimate of appropriate radiotherapy utilization rate for prostate cancer. Int J Radiat Oncol Biol Phys 2003;55:51-63.
46. Foroudi F, Tyldesley S, Walker H, Mackillop WJ. An evidence-based estimate of appropriate radiotherapy utilization rate for breast cancer. Int J Radiat Oncol Biol Phys 2002;53:1240-53.
47. Royal College of Radiologists. Radiotherapy Dose-Fractionation. London: Royal College of Radiologists; 2006.
48. Huyskens D, Bogaerts R, Verstraete J, Loof M, Nystrom H, Fiorino C, et al. Practical guidelines for the implementation of in vivo dosimetry with diodes in external radiotherapy with photon beams (entrance dose). Brussels: ESTRO; 2001.
49. AAPM Report Number 87. Diode in vivo dosimetry for patients receiving external beam radiotherapy. Report of Task Group 62 of the Radiation Therapy Committee. Madison, WI: Medical Physics Publishing; 2005.
50. Royal College of Radiologists. Equipment, Workload and Staffing for Radiotherapy in the UK 1997-2002. London: Royal College of Radiologists; 2003.
51. Scenario Subgroup. Predicting Future Demand for Radiotherapy: National Radiotherapy Advisory Group. London, UK: The Department of Health; 2007.
52. Klein EE, Drzymala RE, Purdy JA, Michalski J. Errors in radiation oncology: a study in pathways and dosimetric impact. J Appl Clin Med Phys 2005;6:81-94.
53. Huang G, Medlam G, Lee J, Billingsley S, Bissonnette J-P, Ringash J, et al. Error in the delivery of radiation therapy: Results of a quality assurance review. International Journal of Radiation Oncology Biology Physics 2005;61:1590-5.
54. Wambersie A, Zreik H, Prignot M, Van Dorpe JC. Variation of RBE as a function of depth in a high energy electron beam in the first millimeters of the irradiated tissues determined by the observation of skin reactions on patients (a clinical trial). Strahlentherapie 1974;148:279-87.
55. Mijnheer BJ. The clinical basis for dosimetric accuracy in radiotherapy. In: Radiation Oncology Committee, editor. Uncertainties, Errors and Accidents in Radiotherapy. London: British Institute of Radiology; 1995.
56. Kearney N, Kidd L, Miller M, Sage M, Khorrami J, McGee M, et al. Utilising handheld computers to monitor and support patients receiving chemotherapy: results of a UK-based feasibility study. Support Care Cancer 2006;14: 742-52.
57. Munro AJ, Potter S. A quantitative approach to the distress caused by symptoms in patients treated with radical radiotherapy. Br J Cancer 1996;74:640-7.
58. Velikova G, Wright P, Smith AB, Stark D, Perren T, Brown J, et al. Self-reported quality of life of individual cancer patients: concordance of results with disease course and medical records. J Clin Oncol 2001;19:2064-73.
59. Macmillan MS, Wells M, MacBride S, Raab GM, Munro A, MacDougall H. Randomized comparison of dry dressings versus hydrogel in management of radiation-induced moist desquamation. Int J Radiat Oncol Biol Phys 2007;68:864-72.
60. Williams MV, James ND, Summers ET, Barrett A, Ash DV. National survey of radiotherapy fractionation practice in 2003. Clin Oncol (R Coll Radiol) 2006;18:3-14.
61. Baker GR, Norton PG, Flintoft V, Blais R, Brown A, Cox J, et al. The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada. CMAJ 2004;170:1678-86.
62. Dean BS, Allan EL, Barber ND, Barker KN. Comparison of medication errors in an American and a British hospital. Am J Health Syst Pharm 1995;52:2543-9.
63. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Br Med J 2004;329:15-9.
64. Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 2007;99:592-600.
65. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003;290: 2685-92.
66. ICRP. 2005 Recommendations of the International Commission of Radiological Protection. Available from: http://www.icrp.org/docs/ 2005_recs_CONSULTATION_Draft1a.pdf [Accessed 1 October 2007].
67. Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. preventive services task force. Ann Intern Med 2002;137:132-41.
68. British Parachute Association. How safe is sport parachuting/sky-diving? Available from: http://www.bpa.org.uk/howsafe.htm [Accessed 1 October 2007].
69. Mascalchi M, Belli G, Zappa M, Picozzi G, Falchini M, Della Nave R, et al. Risk-benefit analysis of X-ray exposure associated with lung cancer screening in the Italung-CT trial. AJR Am J Roentgenol 2006;187:421-9.
70. Department of Transport. Road Casualties Great Britain: 2005. Available from: http://www.dft.gov.uk/pgr/statistics/datatablespublications/accidents/ casualtiesgbar/roadcasualtiesgreatbritain2005 [Accessed 1 October 2007].
71. Phillips L. Return to an Order of the Honourable the House of Commons dated October 2000 for the Report, evidence and supporting papers of the Inquiry into the emergence and identification of Bovine Spongiform Encephalopathy (BSE) and variant Creutzfeldt-Jakob Disease (vCJD) and the action taken in response to it up to 20 March 1996. Available from: http://www.bseinquiry.gov.uk/ [Accessed 1 October 2007].
72. The National Creutzfeldt-Jakob Disease Surveillance Unit. Available from: http://www.cjd.ed.ac.uk/ [Accessed 1 October 2007].
73. Kitchener HC, Castle PE, Cox JT. Chapter 7: Achievements and limitations of cervical cytology screening. Vaccine 2006;24(Suppl 3):S63-70.
74. Li G, Baker SP. Crash risk in general aviation. JAMA 2007;297:1596-8.
75. Vegetarian Society T. General Statistics from the 1990s. Available from: http://www.vegsoc.org/info/statveg90. html [Accessed 1 October 2007].
76. Yeung TK, Bortolotto K, Cosby S, Hoar M, Lederer E. Quality assurance in radiotherapy: evaluation of errors and incidents recorded over a 10 year period. Radiotherapy and Oncology 2005;74:283-91.
77. Ostrom LT, Rathbun P, Cumberlin R, Horton J, Gastorf R, Leahy TJ. Lessons learned from investigations of therapy misadministration events. Int J Radiat Oncol Biol Phys 1996;34:227-34.
78. Voeffray M, Pannatier A, Stupp R, Fucina N, Leyvraz S, Wasserfallen J-B. Effect of computerisation on the quality and safety of chemotherapy prescription. Qual Saf Health Care 2006;15:418-21.
79. Taylor BL, Selbst SM, Shah AE. Prescription writing errors in the pediatric emergency department. Pediatr Emerg Care 2005;21:822-7.
80. Gandhi TK, Bartel SB, Shulman LN, Verrier D, Burdick E, Cleary A, et al. Medication safety in the ambulatory chemotherapy setting. Cancer 2005;104:2477-83.
81. Kim GR, Chen AR, Arceci RJ, Mitchell SH, Kokoszka KM, Daniel D, et al. Error reduction in pediatric chemotherapy: computerized order entry and failure modes and effects analysis. Arch Pediatr Adolesc Med 2006;160:495-8.
82. Ford CD, Killebrew J, Fugitt P, Jacobsen J, Prystas EM. Study of medication errors on a community hospital oncology ward. J Oncol Pract 2006;2:149-54.
83. Engel AF, Oomen JL, Knol DL, Cuesta MA. Operative mortality after colorectal resection in the Netherlands. Br J Surg 2005;92:1526-32.
84. Tekkis PP, Poloniecki JD, Thompson MR, Stamatakis JD. Operative mortality in colorectal cancer: prospective national study. Br Med J 2003;327:1196-201.
85. Strand TE, Rostad H, Damhuis RA, Norstein J. Risk factors for 30-day mortality after resection of lung cancer and prediction of their magnitude. Thorax 2007, in press.